Over 1400 Total Lots Up For Auction at Four Locations - TX 07/30, CA 07/31, MO 08/04, FL 08/05

Dr. Carri Glide-Hurst

American Association of Physicists in Medicine elects fellow
September 04, 2018
Rad Oncology Radiation Therapy
Dr. Carri Glide-Hurst
DETROIT – Henry Ford Cancer Institute medical physicist Carri K. Glide-Hurst, Ph.D., DABR, has been elected to be a Fellow of the American Association of Physicists in Medicine (AAPM), a prestigious international organization of 8,500 medical physicists in 93 countries.

Dr. Glide-Hurst, the director of Translational Research in Radiation Oncology at Henry Ford, was presented with the fellowship award at the Annual Meeting of the American Association of Physicists in Medicine in Nashville, TN.

The category of AAPM Fellow honors members who have distinguished themselves by their contributions in research, education, or leadership in the medical physics community. The AAPM supports the medical physics community with a focus on advancing patient care through education, improving safety and efficacy of radiation oncology and medical imaging procedures through research, and the maintenance of professional standards.
stats
DOTmed text ad

NEW AROBELLA 1000D ADVANCED ULTRASOUND WOUND THERAPY FOR SALE OR RENT

Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds

stats
Dr. Glide-Hurst is nationally recognized for work with magnetic resonance simulation (MR-SIM) and MR‐guided radiation therapy, including implementation at the Henry Ford Cancer Institute of the world’s first FDA-approved linear accelerator-based MRI-guided radiation therapy system, ViewRay MRIdian Linac.

Additionally, Dr. Glide-Hurst was awarded a prestigious NIH R01 on MR-only treatment planning and is primary investigator or co-primary investigator on 11 other grants. She has published 48 manuscripts, four book chapters, 125 abstracts, and holds one patent.

She serves on nine AAPM committees, most notably the Strategic Planning Committee, Board of Directors, co-chair of TG-284 on MR-SIM, Annual Meeting Scientific Track co-director, and AAPM Summer School faculty. She also serves on ABR Medical Physics Parts 2 and 3 Therapy Exam Committees.

Dr. Glide-Hurst also has a passion for mentoring future physicists. During her career, she has mentored 14 residents and 17 researchers.

Dr. Glide-Hurst received a Ph.D. in medical physics from Wayne State University and completed two years of postdoctoral training at Beaumont Health.

You Must Be Logged In To Post A Comment

Medica 2026

 

advertisement

Rad Oncology Homepage

Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities
Will integrate tumor-informed MRD technology with AI-enabled precision oncology platform
Siemens Healthineers reports FAST-02 results for proton Flash radiotherapy
Flash provided pain relief for adults with thoracic bone metastases while producing no adverse events
UW Health Kids opens pediatric interventional radiology suite
Suite includes GE HealthCare’s Allia Moveo image-guidance system
Study finds more than 50 million Americans live in counties without radiation oncology clinics
Between 2018 and 2025, 427 counties experienced a net loss of radiation oncology practice sites
Vanderbilt expands intraoperative PET/CT imaging to breast cancer surgery
Procedure builds on a protocol introduced in 2025 for head and neck cancer surgery
Bridging the gap between innovation and access in prostate cancer care
Insights from Casey Branham, GM of surgical technology services at Agiliti, and Dr. Eugene B. Cone, urologic oncologist at Urology of Indiana
Where the puck is going: A playbook for strategic investments in patient care
Insights from Dr. Eric Whitman, system medical director of Atlantic Health's oncology service line
GT Medical Technologies raises $100 million for GammaTile radiotherapy implant
Company seeks to expand commercialization and advance ongoing clinical research
FDA clears first US human study of IBA’s ConformalFLASH proton therapy
C-FLASH-01 is expected to begin in summer 2026 at the University of Pennsylvania
Olympus to acquire BioProtect in $270 million deal focused on prostate cancer care
Balloon Spacer creates temporary space between prostate and nearby organs during radiation therapy